Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
As part of AHA’s recognition of Mental Health Awareness Month in May, Rebecca Chickey, AHA’s senior director for behavioral health services, writes about the “…
Blog
Language not only describes what we think, but shapes how we think. Many of us remember terms that have fallen out of fashion or even have been deemed…
Perspective
Seventy years ago, George Brock Chisholm, M.D., the first director-general of the World Health Organization, famously stated that “without mental health there…
Headline
Patients went out-of-network 3.5 times more often to see a behavioral health clinician than a medical/surgical clinician in 2021, and up to 20 times more often…
Headline
States can apply through May 20 for up to $2 million to partner with communities to integrate primary and behavioral health care in clinical practices and $900…
Perspective
Two presidents that America honors with a federal holiday on Monday shared a number of memorable traits. George Washington and Abraham Lincoln were blessed…